Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$3.72 USD
+0.04 (0.95%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKBA 3.72 +0.04(0.95%)
Will AKBA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Other News for AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AKBA Stock News
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business ...
Core CPI In Focus With JPMorgan, Goldman, Netflix Set To Report Earnings
Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office